MedTrace Logo

Squamous Cell Carcinoma Antigen Analysis at the University Hospital Ostrava

NCT01827423 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-04-09

No results posted yet for this study

Summary

This prospective study aimed to evaluate the usefulness of squamous cell carcinoma antigen (SCCA) as a clinical marker of sinonasal inverted papilloma (IP). The potential benefit of SCCA in the diagnosis of unilateral nasal pathology and as a marker of hidden recurrence was evaluated as well.

Blood samples from patients with sinonasal IP were examined to determine serum SCCA levels before surgery, the day after surgery, and every 6 months during follow-up. Preoperative and postoperative levels of SCCA were compared.

Conditions

  • Nasal Polyps
  • Nasal Diseases
  • Papilloma

Interventions

DEVICE

Surgical removal of sinonasal papiloma

An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.

Sponsors & Collaborators

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Pavel Kominek, doc.MD,PhD,MBA · University Hospital Ostrava

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827423 on ClinicalTrials.gov